Multi-targeting CAR-T strategies, such as CARs in tandem/dual, bicistronic formats or co-administration/co-transduction and sequential approaches targeting CD19/CD22 or CD19/CD20, have been used in clinical studies in B-ALL as an alternative to avoid these relapses (38–43). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.